Table 5

AUC curve for lncRNA NKILA, NEAT1, MALAT1, MIAT with respect to patients with T2DM with nephropathy versus patients without nephropathy and patients with T2DM with retinopathy versus without retinopathy

GeneAUCCut-offSensitivitySpecificityP value
Patients with T2DM with nephropathy versus without nephropathy
 NKILA0.483.0 fold54%40%0.63
 NEAT10.524.5 fold52%48%0.37
 MALAT10.484.2 fold53%40%0.65
 MIAT0.533.2 fold55%50%0.40
Patients with T2DM with nephropathy versus without nephropathy
 NKILA0.563.1 fold59%41%0.12
 NEAT10.574.6 fold61%51%0.09
 MALAT10.604.3 fold61%50%0.01
 MIAT0.663.5 fold68%58%<0.0001
  • AUC, type 2 diabetes mellitus; lncRNA, long non-coding RNA; MALAT1, metastasis-associated lung adenocarcinoma transcript 1; MIAT, myocardial infarction-associated transcript; NEAT1, nuclear enriched abundant transcript 1; NKILA, NF-kappaB interacting lncRNA; T2DM, type 2 diabetes mellitus.